On Jun. 8, 2020, Intravacc and Versatope announced that they have signed a research service agreement to further develop a universal vaccine against influenza based on Intravaccﾒs innovative Outer Membrane Vesicles (OMV) technology. Both parties will collaborate to further advance the candidate vaccine through clinical development.